IL136603A0 - N-benzyl-3-indenylacetamide derivatives for treating neoplasia - Google Patents

N-benzyl-3-indenylacetamide derivatives for treating neoplasia

Info

Publication number
IL136603A0
IL136603A0 IL13660398A IL13660398A IL136603A0 IL 136603 A0 IL136603 A0 IL 136603A0 IL 13660398 A IL13660398 A IL 13660398A IL 13660398 A IL13660398 A IL 13660398A IL 136603 A0 IL136603 A0 IL 136603A0
Authority
IL
Israel
Prior art keywords
benzyl
indenylacetamide
derivatives
treating neoplasia
arresting
Prior art date
Application number
IL13660398A
Other languages
English (en)
Original Assignee
Cell Pathways Inc
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/989,353 external-priority patent/US5948779A/en
Application filed by Cell Pathways Inc, Univ Arizona filed Critical Cell Pathways Inc
Publication of IL136603A0 publication Critical patent/IL136603A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56Amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13660398A 1997-12-12 1998-12-11 N-benzyl-3-indenylacetamide derivatives for treating neoplasia IL136603A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/989,353 US5948779A (en) 1997-12-12 1997-12-12 Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes
US09/206,245 US6066634A (en) 1997-12-12 1998-12-07 Substituted condensation products of N-benzyl-3-indenylacetamides heterocyclic aldehydes for neoplasia
PCT/GB1998/003712 WO1999031065A1 (en) 1997-12-12 1998-12-11 N-benzyl-3-indenylacetamides derivatives for treating neoplasia

Publications (1)

Publication Number Publication Date
IL136603A0 true IL136603A0 (en) 2001-06-14

Family

ID=26901185

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13660398A IL136603A0 (en) 1997-12-12 1998-12-11 N-benzyl-3-indenylacetamide derivatives for treating neoplasia

Country Status (18)

Country Link
US (3) US6166053A (enExample)
EP (1) EP1044187B1 (enExample)
JP (1) JP4307719B2 (enExample)
CN (1) CN100436418C (enExample)
AT (1) ATE257152T1 (enExample)
AU (1) AU752072B2 (enExample)
BR (1) BR9813540A (enExample)
CA (1) CA2314339C (enExample)
CZ (1) CZ298826B6 (enExample)
DE (1) DE69820908T2 (enExample)
ES (1) ES2212383T3 (enExample)
HU (1) HU227153B1 (enExample)
IL (1) IL136603A0 (enExample)
NO (1) NO317097B1 (enExample)
NZ (1) NZ504958A (enExample)
PL (1) PL196936B1 (enExample)
TR (1) TR200001687T2 (enExample)
WO (1) WO1999031065A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2314339C (en) * 1997-12-12 2009-09-08 Cell Pathways, Inc. N-benzyl-3-indenylacetamide derivatives for treating neoplasia
IL132366A0 (en) * 1998-10-15 2001-03-19 Cell Pathways Inc Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds
AU2001255849B8 (en) * 2000-04-19 2006-04-27 Lilly Icos, Llc. PDE-V inhibitors for treatment of Parkinson's Disease
DE10058663A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Thienopyrimidinen
WO2002067936A1 (en) * 2001-02-21 2002-09-06 Cell Pathways, Inc. Methods for treatment of inflammatory bowel disease
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
US20030073740A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of lupus erythematosus
US6479493B1 (en) * 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US20030073711A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of scleroderma
CN100398522C (zh) * 2003-08-20 2008-07-02 Irm责任有限公司 组织蛋白酶s的抑制剂
US6995622B2 (en) * 2004-01-09 2006-02-07 Robert Bosh Gmbh Frequency and/or phase compensated microelectromechanical oscillator
CA2568906C (en) 2004-06-02 2010-09-21 Merit Diamond Corporation Comfort interior for jewelry and jewelry including that interior
CN1332930C (zh) * 2005-08-05 2007-08-22 中国科学院上海有机化学研究所 制备乙氰菊酯前体的方法
CA2635093C (en) * 2006-01-04 2012-06-26 Southern Research Institute Derivatives of sulindac, use thereof and preparation thereof
WO2009022756A1 (ja) * 2007-08-13 2009-02-19 Katayama Chemical Industries Co., Ltd. 虚血性疾患の診断及び治療
EP2365746B1 (en) * 2008-11-04 2014-07-16 Wellstat Therapeutics Corporation Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids
CN109703393A (zh) 2009-08-07 2019-05-03 奥克兰联合服务有限公司 感应电力传递装置
US20160168108A1 (en) 2014-12-16 2016-06-16 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases
US9862698B2 (en) 2014-12-16 2018-01-09 Adt Pharmaceuticals, Inc. Indenyl compounds, pharmaceutical compositions, and medical uses thereof
CN112020354A (zh) 2018-04-26 2020-12-01 Adt制药有限责任公司 抗癌茚类、茚满类、氮杂茚类、氮杂茚满类、药物组合物和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650720B2 (en) * 1991-03-08 1994-06-30 Fgn, Inc. Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof
US6063818A (en) * 1996-06-13 2000-05-16 Cell Pathways Inc. Substituted benzylidene indenyl formamides, acetamides and propionamides
US5948779A (en) * 1997-12-12 1999-09-07 Cell Pathways, Inc. Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes
CA2314339C (en) * 1997-12-12 2009-09-08 Cell Pathways, Inc. N-benzyl-3-indenylacetamide derivatives for treating neoplasia

Also Published As

Publication number Publication date
NZ504958A (en) 2003-03-28
PL341151A1 (en) 2001-03-26
PL196936B1 (pl) 2008-02-29
NO20002972L (no) 2000-08-09
CA2314339A1 (en) 1999-06-24
US6426349B1 (en) 2002-07-30
EP1044187A1 (en) 2000-10-18
HUP0100170A3 (en) 2001-12-28
TR200001687T2 (tr) 2000-10-23
DE69820908T2 (de) 2004-12-23
ATE257152T1 (de) 2004-01-15
AU1498199A (en) 1999-07-05
AU752072B2 (en) 2002-09-05
NO20002972D0 (no) 2000-06-09
NO317097B1 (no) 2004-08-09
HUP0100170A1 (hu) 2001-07-30
DE69820908D1 (de) 2004-02-05
CZ298826B6 (cs) 2008-02-20
WO1999031065A1 (en) 1999-06-24
CA2314339C (en) 2009-09-08
BR9813540A (pt) 2000-10-10
ES2212383T3 (es) 2004-07-16
EP1044187B1 (en) 2004-01-02
HU227153B1 (en) 2010-08-30
CZ20002157A3 (cs) 2000-10-11
JP2002508358A (ja) 2002-03-19
US20030009033A1 (en) 2003-01-09
US6166053A (en) 2000-12-26
JP4307719B2 (ja) 2009-08-05
US6610854B2 (en) 2003-08-26
CN100436418C (zh) 2008-11-26
CN1281436A (zh) 2001-01-24

Similar Documents

Publication Publication Date Title
IL136603A0 (en) N-benzyl-3-indenylacetamide derivatives for treating neoplasia
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
HU9301314D0 (en) Quinazoline derivatves for improving anto-tumouric activity
AU3382284A (en) Microwave hyperthermia
HU9302384D0 (en) 2,4-diamino-quinazoline derivatives and medical preparatives containing them
NZ333399A (en) Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
MY138883A (en) Use of asiatic acid for treatment of cencer
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
WO2000055629A3 (en) Methods of diagnosing and treating breast cancer
ES2167401T3 (es) Uso de ascorbil-gamma-linolenato o un ascorbil-dihomo-gamma-linolenato para el tratamiento de asma, cancer, enfermedades cardiovasculares y anti-inflamatorias.
PL375527A1 (en) Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases
PT971710E (pt) Utilizacao de queleritrina e radiacao para terapia de tumores
ZA982136B (en) Novel carboxylic acid derivatives, their preparation and use in treating cancer.
CA2298820A1 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
ATE353016T1 (de) Chelatiertes 8-hydroxychinolin zur behandlung von epithelialen verletzungen
BR9808958A (pt) Formulações de óxidos de 1,2,4-benzotriazina
ZA9711677B (en) Surface material for absorbent articles, absorbent articles that include the surface material, and the use of the material in absorbent articles.
AU1128801A (en) Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth
WO1998007415A3 (en) Methods for prevention of cellular proliferation and restenosis
WO2001036048A8 (en) Phorboxazole derivatives for treating cancer
IL164356A0 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
Williams Falsified information did not change the conclusions of NSABP B 06 supporting lumpectomy plus radiation therapy for breast cancer
MY105075A (en) Cancer treatment
FI964672A0 (fi) Viljankäsittelymenetelmä, käsitelty vilja ja sen käyttö

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed